ProAgio, a Novel Integrin αvβ3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment
Targeting integrin αvβ3 using ProAgio modulates the PDAC TME by improving perfusion, reducing hypoxia, reversing EMT, and alleviating immune suppression. ProAgio potentiates the effects of GPH therapy, which should be evaluated in future trials.
Authors
- Jeremy B. Foote (ORCID: https://orcid.org/0000-0002-6621-6096)
- Sujith Sarvesh
- Bassel F. El‐Rayes (ORCID: https://orcid.org/0000-0002-2661-5746)
- M. Malla
- Harrision Kim
- Ganji P Nagaraju
Institutions
- Indiana University Health (US)
- Augusta University (US)
- University of Alabama at Birmingham (US)
- Augusta University Health (US)
- Indiana Cancer Consortium (US)
- The Ohio State University (US)
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-01-16
- DOI
- https://doi.org/10.64898/2026.01.15.699725
- Primary Topic
- Cell Adhesion Molecules Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00